UPDATE: Morgan Stanley Upgrades Alkermes To Equal-Weight, Lowers Target To $20 As Firm Notes 'Shares have underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent'